Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2nd Nordic Mantle-Cell Lymphoma protocol
ISRCTN87866680Phase 2Completed
- Sponsor
- Individual sponsor
- Start
- Apr 2001
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone and 4 more in mantle cell lymphoma (MCL), sponsored by Individual sponsor. Primary endpoint: Event-free survival. Started Apr 2001; status: completed.
02
Drugs
rituximabcyclophosphamidedoxorubicinvincristineprednisolone
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on ISRCTN87866680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN87866680.